# BPC-157 Research: Multi-Tissue Evidence and the Human Pilots > BPC-157 research spans tendon, gastric, vascular, and organ-protection models, with three small human pilots so far. The cited preclinical record, the benefits reported, and the oral-stability question. A broad, reproducible animal literature; three small human pilots; and one honest edge — most of the foundational work comes from a single research group, and large controlled human trials are lacking. ## BPC-157 Benefits Reported Across the Preclinical Literature BPC-157 research has reported repair and protection across a wide span of tissues, and the consistency of the animal record is itself a finding worth stating. In a fully transected rat Achilles tendon, BPC-157 improved biomechanical and functional recovery, produced better collagen organization, and restored tendon integrity versus untreated controls, while stimulating tendocyte outgrowth in vitro [1]. In rat gastric ulcers, intramuscular and intragastric dosing accelerated healing, with the higher doses inhibiting ulcer formation by 45.7-65.6% and intramuscular delivery outperforming intragastric [4]. A 2021 review consolidated the wound-healing evidence across skin, muscle, tendon, ligament, and bone, organizing it around the peptide's cytoprotective and angiogenic mechanism [5]. More recent rat work reports protection of distant organs — liver, kidney, and lung — in acute pancreatitis [13], and a 2026 rat study reports resolution of a tracheocutaneous fistula attributed to the nitric-oxide system [11]. A 2025 literature-and-patent review catalogued the breadth of this multifunctional preclinical activity [9]. The common thread across this range — the [mechanism of action](/angiogenesis) the corpus centers — is pro-angiogenic VEGFR2 signaling, which is why the breadth is not as scattered as the tissue list first suggests. The benefits reported above are animal-model findings. They describe what was measured in rodents, not outcomes established in people. The human picture, set out below, is far smaller. ## The Three Human Pilots — Small, Uncontrolled, Reassuring So Far Human BPC-157 data is extremely limited. As of 2025 reviews, exactly three small human pilot studies exist [8]. A 2025 first-in-human safety pilot infused intravenous BPC-157 up to 20 mg in two healthy adults; it was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid, or glucose biomarkers [7]. A 2024 pilot in 12 interstitial-cystitis patients reported that a single intravesical dose during cystoscopy was associated with symptom resolution in most patients, with no reported adverse events [12]. A 2021 case series reported that intra-articular injection was associated with improvement across multiple types of knee pain, again uncontrolled and without a comparator [6]. One historical industrial program (PL 14736 / PLD-116) reported BPC-157 was safe in early inflammatory-bowel-disease trials. But none of this is a controlled efficacy trial. A 2025 narrative review concluded that despite broad preclinical support, the human evidence is too thin to draw efficacy conclusions, and that BPC-157 should be considered investigational [8]. ## Does BPC-157 really work? Most BPC-157 evidence is preclinical. A 2025 narrative review found only three small human pilot studies and concluded that rigorous, large-scale controlled trials are lacking, so efficacy in humans is not established [8]. The animal record is broad and reproducible, but reproducibility in rodents is not the same as a demonstrated human effect. The honest reading is: promising preclinical signal, minimal human data. ## What are the potential uses and benefits of BPC-157? Preclinical work spans tendon, ligament, bone, muscle, gut, vascular, and organ-protection models, with reported benefits including accelerated tendon healing [1], gastric-ulcer cytoprotection [4], and distant-organ protection in pancreatitis [13]. These are animal-model findings. Only three small uncontrolled human pilots exist so far [8], so "potential uses" remains the right framing — the literature describes possibilities under study, not validated human indications. ## Oral BPC-157 and the Gastric-Stability Question Interest in oral BPC-157 rests on a specific claim: the peptide is termed a "stable gastric pentadecapeptide" because it is reported to be stable in human gastric juice, which is why peroral administration has been studied at all [5]. Several rodent models have used intragastric or peroral routes [4]. That said, formal human oral pharmacokinetics are not established. Stability in gastric juice is not the same as characterized oral absorption, and the animal pharmacokinetic work that does exist used intravenous and intramuscular routes [2]. So oral BPC-157 is a real line of research grounded in a reported stability property — but the human oral profile remains uncharacterized, and any oral "protocol" circulating outside the literature is not validated science. ## An Honest Note on the Evidence Base Two caveats sit over the entire BPC-157 record. First, a large share of the foundational literature comes from a single research group, which newer authors explicitly flag as raising independent-replication questions [8]. Several 2024-2025 reviews continue to advance the cytoprotective framing and a generally reassuring preclinical safety picture — including a 2025 review focused on protection following intoxications [14] and a 2025 commentary reasserting the cytoprotectant model [15] — but reviews from within the same tradition are not a substitute for independent controlled trials. Second, common online claims — weight loss, muscle building, increased testosterone — are not supported by the published evidence and should be treated skeptically. The studies summarized here measure tissue repair and protection in animals and a handful of people; they do not establish the metabolic or performance effects often asserted in marketing copy. --- A color-blocked reading board for the BPC-157 record — each tissue, the VEGFR2 mechanism, the three human pilots, and the FDA 503A status set in its own plum-and-pop panel and cited to source, with no clinic behind the board and nothing here dispensed or sold.